Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancers, and 55% of all HCC cases worldwide are reported from China. In Hong Kong, liver cancer is the fourth most common cancer and the third most common cause of cancer death.
On 14 January 2019, the FDA approved cabozantinib (Cabometyx®, Exelixis) for hepatocellular carcinoma (HCC) patients previously treated with sorafenib.
On 19 December 2017, the FDA granted regular approval to cabozantinib (Cabometyx®, Exelixis) for treatment of patients with advanced renal cell carcinoma (RCC).
There is no excerpt because this is a protected post.